As filed with the Securities and Exchange Commission on January 20, 2021 Registration No. 333- ...
CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference Live video webcast...
CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq...
0001729427 false 0001729427 2022-01-10 2022-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference PR Newswire HOUSTON, Jan. 7, 2022...
CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of...
CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event Live moderated video webcast...
LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a...
CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate...
0001729427 false 0001729427 2021-08-13 2021-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook Recently...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.